We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
About this guideline
Overseas effective date: 1 September 2016
Replaces: EMEA/CHMP/BWP/157653/2007 Guideline on Development, Production, Characterisation and Specifications for Monoclonal Antibodies and Related Products (adopted by TGA 5 August 2009); and the quality requirements for monoclonal antibodies set out in the guideline 3AQ21a Radiopharmaceuticals Based on Monoclonal Antibodies (adopted by TGA 12 February 2002)
Categories: Biologicals | Active substance | Manufacture and characterisation and control of the active substance
TGA annotations: Nil
- Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
- All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.
For more information see International scientific guidelines adopted in Australia.